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The antifungal peptides represent diverse structures for drug design. Unfortunately, they 
provide inferior drug candidates because of their low oral bioavailability, potential 
immunogenicity, poor in vivo metabolic stability and high molecular weight. Recent 
efforts have focused on the creation of non-natural peptide mimetics. Their artificial 
backbone makes most peptidomimetics resistant to degradative enzymes, thus, 
increasing the stability of peptidomimetic drugs in the body. In the present study, four 
antifungal peptidomimetics structures named C1 to C4 were designed based on the 
antifungal decapeptide crystallized structure of Pep-1 using bioinformatics tools. 
Structures C1 and C2 belong to the N-terminal part of Pep-1 and C3 and C4 belong to the 
C-terminal amino acid sequence part of Pep-1. Minimum inhibitory concentrations 
(MIC) of these structures were estimated against Aspergillus niger N402, Candida 
albicans ATCC 10231, and Saccharomyces cerevisiae PTCC 5052. Structures C2 and 
C1 showed more potent antifungal activities against these fungal strains compared to C3 
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and C4, respectively. This demonstrated that the N-terminal part is more potent for 
antifungal activity and indicated that the N-terminal part of antifungal peptides is more 
active and important for antifungal activity than the C-terminal. Structure C2 was 
demonstrated to be more active against these microorganisms and could be used as a 
potential target for future antifungal peptidomimetics studies. Important 
factors/descriptors of 63 antifungal peptides have been studied using Artificial Neural 
Network (ANN). The most important factors determined were amino acid number 1 
(S1), Log P, and their α-helix contents. This is the first study on the structure of C1 to C4 
peptidomimetics on Aspergillus niger N402, Candida albicans ATCC 10231, and 
Saccharomyces cerevisiae PTCC 5052. 
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Peptida antikulat merupakan struktur yang pelbagai bagi rekabentuk dadah. Malangnya, 
mereka membekalkan calon dadah yang berkualiti rendah disebabkan biopenggunaan 
oral yang rendah, potensi imunogenisiti, kestabilan metabolik in vivo yang rendah dan 
berat molekul yang tinggi. Usaha terkini tertumpu kepada penciptaan peptida mimetik 
yang tidak asli. Tulang belakang peptida mimetik yang tidak asli ini menyebabkan 
kebanyakan peptida mimetik rintang terhadap enzim degradatif dan meningkatkan 
kestabilan bahan dadah peptida mimetik tersebut didalam tubuh. Dalam kajian ini, 
empat struktur peptida mimetik antikulat (C1 – C4) di reka bentuk berasaskan struktur 
terhablur dekapeptida antikulat Pep-1 dengan menggunakan kaedah bioinformatik.  
Struktur C1 dan C2 terkandung dalam bahagian terminal-N struktur antikulat Pep-1 
sementara struktur C3 dan C4 terkandung dalam bahagian jujukan asid amino terminal-C 
antikulat Pep-1.  Kepekatan perencatan minimum (Minimum inhibitory concentration, 
MIC) struktur tersebut dianggar dengan menggunakan kulat Aspergillus niger N402, 
Candida albicans ATCC 10231 dan Saccharomyces cerevisiae PTCC 5052. Struktur C2 
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dan C1 menunjukkan aktiviti antikulat yang kuat terhadap ketiga-tiga species kulat yang 
dikaji berbanding C3 dan C4. Ini membuktikan bahawa bahagian terminal-N 
mengandungi aktiviti antikulat yang lebih kuat berbanding terminal-C dan bahagian 
terminal-N peptida antikulat adalah lebih aktif dan penting dari terminal-C.  Struktur C2 
mempamerkan aktiviti antikulat yang tinggi terhadap kulat yang dikaji dan 
berkemungkinan menjadi sasaran untuk kajian masa hadapan bagi peptida mimetik 
antikulat.  Kajian ke atas 63 peptida antikulat telah dilakukan dengan menggunakan 
jaringan artifisial neural (Artificial Neural Network, ANN). Faktor paling penting yang 
ditentukan ialah asid amino pertama dalam jujukan (S1), Log P dan isi kandungan α-
heliks. Kajian ini merupakan kajian pertama keatas struktur C1 hingga C4 peptida 
mimetik Aspergillus niger N402, Candida albicans ATCC 10231, dan Saccharomyces 
cerevisiae PTCC 5052. 
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CHAPTER I 
 INTRODUCTION 
 
 
1.1. Background and Objectives 
In the past 10 years, the frequency of fungal disease has increased noticeably (Hong 
et al., 2001). Multiple-drug resistances have appeared leading to the discovery of 
novel drugs to combat the through diverse mechanisms of actions. Antimicrobial 
peptides (AMPs) are an evolutionarily conserved component of the innate immune 
response and are found among all classes of life. These peptides are potent, broad 
spectrum antibiotics which demonstrate potential as novel therapeutic agents. These 
AMPs are finding from diverse sources ranging from primary eukaryotes to 
mammalian having typically fewer than 60 amino acids long, containing cationic 
amino acid residues and an amphiphilic structure bound to the membrane (α-helical 
and/or β-sheet). Many of these peptides are unstructured in free solution, and fold 
into their final configuration upon partitioning into biological membranes.  
The ability to associate with membranes is a definitive feature of antimicrobial 
peptides (Dhople, et al. 2006) although membrane permeabilisation is not necessary. 
These peptides have a variety of antimicrobial activities ranging from membrane 
permeabilization to action on a range of cytoplasmic targets.  It appears as though 
many peptides initially isolated as and termed “antimicrobial peptides” have been 
shown to have more significant alternative functions in vivo (e.g. hepcidin) 
(Brogden, 2005).  These peptides are excellent candidates for development as novel 
therapeutic agents and complements to conventional antibiotic therapy because in 
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contrast to conventional antibiotics they do not appear to induce antibiotic resistance 
while they generally have a broad range of activity, are bacteriocidal as opposed to 
bacteriostatic and require a short contact time to induce killing.  
A number of naturally occurring peptides and their derivatives have been developed 
as novel anti-infective therapies for conditions as diverse as oral mucositis, lung 
infections associated with cancer (Amsterdam, 1996), and topical skin infections. 
Pexiganan has been shown to be useful to treat infection related diabetic foot ulcer.  
The application of peptides as drugs is difficult due to their poor oral and tissue 
absorption, quick proteolytic cleavage and weak half-life or stability. Since the 
majority of proteins and small peptides are simply proteolyzed, quickly excreted and 
poorly bioavailable, a lot attempt has been exhausted to discover ways to replace 
portions of peptides with non-peptide structures, termed peptidomimetics which are 
to mimic peptide in the expectation of achieving more bioavailable units. Their 
artificial backbone is resistant to proteases, as well.  Peptidomimetics are one set of 
probes utilized in the shift pathway of tiny molecule drug design.  
In recent times considerable advancement has been made in use of Computer-Aided 
Molecular Design (CAMD) of novel molecules. These techniques normally rely on 
two steps: the first being forward modelling, through which Quantitative Structure 
Activity Relationship (QSAR) procedure is accomplished by application of non-
linear modelling procedures such as Artificial Neural Networks (ANN). The second 
step is model inversion/optimization which utilizes optimization of algorithms in 
exploitation of the first stage result in discovery of molecules with enhanced activity. 
Several factors have an effect on the activity of antifungal peptides like sequence, 
size, charge, degree of structure formation, cationicity, hydrophobicity, 
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amphipathicity, hydrophobic moment and pH. ANN possibly will aid us to calculate 
approximately the significance of these structural parameters in bioactivity of AFPs 
and finally the most possible model of AFPs’ mechanism of action.  
In the current study, important factors/descriptors in antifungal peptides have been 
studied and 4 antifungal peptidomimetics structures were designed based on 
antifungal peptide structures, using different design methods by means of 
bioinformatics as a computational studies, rather than synthesize first and test 
antimicrobial peptidomimetics strategy.  
 
Objectives:  
Two objectives have been followed in this study which are: 
 
1. In silico study of potential features/descriptors in antifungal peptides 
molecules. 
 
2. Design of antifungal peptidomimetics structure using 
cheminformatics/bioinformatics tools. 
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CHAPTER II 
LITERATURE REVIEW 
 
2.1. Antimicrobial Peptides 
2.1.1. Introduction 
Multi-drug resistance against generally used antibiotics has turn into an essential 
community health trouble all over the world (Lohner, 2001; Novak et al., 1999). 
Although the occurrence of resistance is not new, being first proposed by Sir 
Alexander Fleming with regard to penicillin more than 60 years in the past, it has 
become of greater than ever concern as more and more antibiotics are caused to be 
ineffective. Furthermore, resistance at this moment also includes effective 
antibacterial agents which are used as a last resort, e.g. methicillin and vancomycin. 
Around 30% of hospital strains of Enterococci are vancomycin resistant and almost 
half of the infections caused by Staphylococcus aureus are methicillin resistant 
(Straus and Hancock, 2006). In the last two decades, the occurrence of human fungal 
infections has increased significantly; in parallel with the broad extend of untreatable 
infectious diseases connected with antibiotic resistant bacteria (Jang et al., 2006). Of 
the thousands of recognized fungal species, just about 175 are pathogenic and 
generate mycotic infections in humans and animals (Duggineni et al., 2007).  As of 
2003, over 57% of Staphylococcus aureus infections in US intensive care units were 
resistant to multiple antibiotics (National Nosocomial Infections Surveillance (NNIS) 
System Report). Fungal infections are significant reasons of morbidity and mortality 
in hospitalized patients: candidiasis is the fourth most general blood culture isolates 
in US hospitals (Pfaller et al., 1998), pulmonary aspergillosis is the leading cause of 
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death in bone marrow transplant recipients (Panutti et al., 1992), and Pneumocystis 
carinii pneumonia is the leading cause of death in AIDS patients in North America 
and Europe fungal diseases have been converted into an emergent hazard, principally 
in immunocompromised patients, for which few or no effective drugs are currently 
obtainable (Lupetti et al., 2002). The incidence of fungal infections that have been 
seen in the increasing populations of immunocompromised hosts, counting 
individuals infected with HIV, aging, organ transplantation, and patients with cancer, 
has increased dramatically in the last few decades (Peara & Patterson, 2002). The 
AIDS epidemic, enhanced life-sustaining therapy, and aggressive anticancer therapy 
have supplied to the increase in the quantity of severely immunocompromised 
patients (Helmerhorst et al., 1999). This has led to a raise in mucosal and systemic 
fungal infections, and the simultaneous increased usage of antifungal agents for 
prophylaxis is most likely the main reason of the improvement of antifungal drug 
resistance (White et al., 2001).  
The yeast fungus, Cryptococcus neoformans, has been recognized as the fourth most 
regular from of life-threatening infection in AIDS patients (White et al., 2001). 
Potentially fatal infections with Candida albicans and other species of Candida are 
in addition identified (Kovacs et al., 1985). Additionally, antifungal drugs frequently 
make use of various unfavourable effects and are irregularly dose-limiting. In such 
conditions, a novel scheme is for the control of fungal infections. Aspergillosis and 
candidiasis, which are typically caused by Aspergillus fumigatus and Candida 
albicans, respectively, are the most repeated of fungal infections (Clark & Hajjeh, 
2002). In agriculture, enormous economic losses are caused by the infestation of crop 
plants with fungal pathogens (Szappanos et al., 2006). The infection with plant 
pathogens such as Fusarium spp. not only causes severe yield losses, crop damage 
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and decreases in quality of grain, but far more considerably, may also pollute the 
grain with mycotoxins, which are dangerous to animal and human wellbeing 
(Edwards, 2004). Human fungal pathogens are exceedingly different group of fungal 
species, and Candida albicans, Aspergillus fumigatus, and Crytococcus neoformans 
are the three most significant pathogens causing severe systemic infections among 
the immunocompromised population (Groll & Walsh, 2001).  
At this time, efficient drug therapy to treat fungal infections is very limited and 
dominated by the azole class of antifungals, which selectively inhibit lanosterol 
demethylase activity, a late step in ergosterol biosynthesis (Geogopapadakou & 
Walsh, 1996; Green et al., 1999; Sheehan et al., 1999). Although the azole 
antifungals have admirable safety profiles and are orally bioavailable, they are not 
fungicidal and therefore have need of long therapeutic treatment. Subsequently, their 
extensive use has led to an increasing incidence of drug resistance (Sussman et al., 
2004).   
Scientists have consequently concentrated their efforts on the design and 
advancement of new classes of antimicrobial agents that acquire novel modes of 
action that could conquer recognized mechanisms of antibiotic resistance. An 
attractive approach consists of probing for naturally occurring antibiotic molecules 
and both the plant and animal kingdom are rich sources. For that reason, in the search 
for an alternative form of treatment for fungal infections, the last decade has seen a 
spreading out in innovative approaches, like therapeutic antibodies and peptide 
molecules (Hancock, 1999; Kumar et al., 2005). Accordingly, there is a greater 
concern in the pharmacological application of antimicrobial peptides to treat 
infection, and the development of a new class of anti-infective agents.  
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Antimicrobial peptides are capable candidates for novel therapeutic agents because 
of their low toxicity against mammalian cells, do not easily select resistant mutants 
(Duggineni et al., 2007), and are therapeutic agents against microbes and their unique 
biological mechanisms of perturbing the membrane of the pathogen (Hong et al., 
2001). They are a new resource of potential new antibiotic drugs because they were 
proposed to interact directly with lipid bilayers, resulting in pore-forming or 
alteration of the cell membrane permeability and eventually cell death (Sitaram & 
Nagaraj, 1999; Shai, 1999). On the other hand, some of these agents have got to 
clinical trials, whereas others are undergoing detailed preclinical testing (Hancock 
1999), the search for such antifungal peptides continues, especially in selecting an 
effective candidate for the development of a new type of antibiotic. Antimicrobial 
peptides (AMPs) make natural antibiotics the basic element of a novel generation of 
drugs for the treatment of bacterial and fungal infections (Delucca, 2000; Welling et 
al., 2000; Selitrennikoff, 2001). Figure 2.1 shows that these peptides are made by 
many cells in skin and have multiple functions. Peptides are expressed in layers 
providing antimicrobial barrier at surface when secreted by eccrine glands and can be 
made by keratinocytes when activated. Resident and recruited bone marrow-derived 
cells such as mast cells and neutrophils also express high levels of antimicrobial 
peptides. Functions attributed to these peptides extend well beyond activity as simple 
antibiotic. Select molecules will influence cytokine release and synthesis of 
components of the extracellular matrix (ECM), and are chemotactic and angiogenic 
(Izadpanah & Gallo, 2005).  
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 Figure 2.1. Antimicrobial peptides are made by many cells in the skin and have 
multiple  functions. (Source: Izadpanah & Gallo, 2005) 
 
 
AMPs, effectors molecules of the innate immune system, present a first line of 
defense against invading pathogens, promise to be a solution to this problem (Ganz, 
1999; Lohner & Epand, 1997). Antimicrobial peptides are small molecules that serve 
in the vertebrate and invertebrate world for both offensive and defensive purposes as 
part of the immune defense system (Shai, 1999). Figure 2.2 describes some functions 
of AMPs.  
 
 
 
 
 
 
 
 
 
